Open-to-Accrual Therapeutic Trials


Protocol ID

Official Title

PI Name

Lead CRC

Disease Site


CC-16047   NCT02834052 A phase I/II trial of pembrolizumab (MK-3475) and poly-ICLC in patients with metastatic mismatch repair-proficient (MRP) colon cancer A. Nayak Kelly Jenkins Phase 1: All solid tumors, following at least one therapy  Phase 2: Mismatch Repair Proficient “MRP” (includes microsatellite stable [MSS] and MSI-low) colon cancer that has progressed following at least two lines of therapy I/II
CC-16053 NCT03257722 A phase Ib /II trial of pembrolizumab and idelalisib in patients with non-small cell lung cancer (NSCLC) who have failed immune checkpoint inhibitor A. Nayak / Z. Hao Kelly Jenkins Non-Small Cell Lung Cancer (NSCLC) I/II
Tesaro 4010-01-001 NCT02715284 Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors S. Ghamande Lisa Marshall & Kelly Jenkins Solid Tumor I
NLG-2104 NCT02077881 A Phase 1/2 Study of Indoximond in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Adenocarcinoma of the Pancreas A. Nayak Lisa Marshall Pancreatic Adenocarcinoma I/II
NLG-2105  NCT02502708 Phase 1 Trials of Indoximod in Combination with Temozolomide-based Therapy for Children with Progressive Primary Brain Tumors T. Johnson Robin Dobbins & Kimberly Gray Pediatric Brain Tumor I
NLG-2106 NCT02835729 A Phase 1b/Randomized Phase 2a Trial of Indoximod in Combination with Idarubicin and Cytarabine in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) J. Pantin Sandra Wall Acute Myeloid Leukemia (AML) I/II